Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick T F Kennedy

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Gut|February 1, 2019
HBV antiviral immunity: not all CD8 T cells are born equalAntonio Bertoletti, Patrick T F Kennedy
Expert Review of Anti-Infective Therapy|July 24, 2014
Chronic hepatitis B virus in young adults: the need for new approaches to managementUpkar S Gill, Patrick T F Kennedy
Gut|February 1, 2020
Hepatitis B reactivation: reducing the risk in patients with inflammatory bowel diseaseGrace Elizabeth Dolman, Patrick T F Kennedy
Journal of Viral Hepatitis|November 12, 2018
The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeuticsUpkar S Gill, Patrick T F Kennedy
Journal of Hepatology|June 21, 2017
Current therapeutic approaches for HBV infected patientsUpkar S Gill, Patrick T F Kennedy
Gut|December 3, 2017
HBV infection and HCC: the 'dangerous liaisons'Antonio Bertoletti, Patrick T F Kennedy, David Durantel
Journal of Viral Hepatitis|December 2, 2022
Hepatitis delta virus: Disease assessment and stratificationApostolos Koffas, Lung-Yi Mak, Patrick T F Kennedy
Gastroenterology|March 9, 2017
ReplyPatrick T F Kennedy, Antonio Bertoletti, William S Mason
Expert Review of Anti-Infective Therapy|November 19, 2019
Emerging tools in the changing landscape of chronic hepatitis B managementUpkar S Gill, Arianna Battisti, Patrick T F Kennedy
Gut|May 27, 2020
Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisisGeorgia Zeng, Upkar S Gill, Patrick T F Kennedy
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Gut|February 1, 2019
HBV antiviral immunity: not all CD8 T cells are born equalAntonio Bertoletti, Patrick T F Kennedy
Expert Review of Anti-Infective Therapy|July 24, 2014
Chronic hepatitis B virus in young adults: the need for new approaches to managementUpkar S Gill, Patrick T F Kennedy
Gut|February 1, 2020
Hepatitis B reactivation: reducing the risk in patients with inflammatory bowel diseaseGrace Elizabeth Dolman, Patrick T F Kennedy
Journal of Viral Hepatitis|November 12, 2018
The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeuticsUpkar S Gill, Patrick T F Kennedy
Journal of Hepatology|June 21, 2017
Current therapeutic approaches for HBV infected patientsUpkar S Gill, Patrick T F Kennedy
Gut|December 3, 2017
HBV infection and HCC: the 'dangerous liaisons'Antonio Bertoletti, Patrick T F Kennedy, David Durantel
Journal of Viral Hepatitis|December 2, 2022
Hepatitis delta virus: Disease assessment and stratificationApostolos Koffas, Lung-Yi Mak, Patrick T F Kennedy
Gastroenterology|March 9, 2017
ReplyPatrick T F Kennedy, Antonio Bertoletti, William S Mason
Expert Review of Anti-Infective Therapy|November 19, 2019
Emerging tools in the changing landscape of chronic hepatitis B managementUpkar S Gill, Arianna Battisti, Patrick T F Kennedy
Gut|May 27, 2020
Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisisGeorgia Zeng, Upkar S Gill, Patrick T F Kennedy
Pageof 7